Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 20;7(1):16.
doi: 10.1186/s41256-022-00249-z.

Experience on the first national anti-TB drug resistance survey (DRS) in Timor-Leste

Constantino Lopes  1 , Debashish Kundu  2 , Ismael Da Costa Barreto  3 , Bernardino da Cruz  4 , S Siva Kumar  5 , Sureshbabu Ramalingam  3   6 , Anna S Dean  7 , Vineet Bhatia  8 , Prabhu Seenivasan  5 , C Padmapriyadarsini  5 , Olga Tosas Auguet  7
Affiliations

Experience on the first national anti-TB drug resistance survey (DRS) in Timor-Leste

Constantino Lopes et al. Glob Health Res Policy. .

Abstract

Background: A national drug resistance survey (DRS) was implemented for the first time in Timor-Leste (TL) in 2019. The primary objective of the survey was to assess the prevalence of drug resistance among new and previously treated pulmonary TB patients in the country.

Methods: This nation-wide cross-sectional survey was conducted in 2019 targeting all new and previously treated sputum smear-positive pulmonary TB patients. Sputum samples were submitted to the National TB Reference Laboratory for confirmation of TB and to determine resistance to rifampicin by Xpert MTB/RIF. Culture was performed on solid media, and culture isolates of confirmed TB cases were shipped to the WHO Supranational TB Reference Laboratory in Chennai, India for whole genome sequencing (WGS). Survey summary statistics, data cross-tabulations and analysis of potential risk factors of rifampicin-resistant TB (RR-TB) were conducted using R statistical software (version 3.5.2).

Results: A total of 953 sputum-smear positive patients were enrolled, of which 917 were confirmed as positive for TB by either Xpert MTB/RIF or culture. An electronic web-based system was used for entry and storage of the data. Rifampicin resistance was detected among 0.6% (95% CI 0.2-1.3) of new cases and 2.7% (95% CI 0.5- 8.2) of previously treated cases. WGS was conducted for validation purposes on 65 randomly selected isolates (29% of RR-TB (2/7) and 7% of RS-TB (63/910) by Xpert MTB/RIF or pDST). The original test results agreed with the WGS validation results for 62/64 isolates (97%).

Conclusion: The prevalence of RR-TB in Timor-Leste is relatively low compared to the estimated proportions of RR-TB in the WHO South-East Asia Region (2.5% [95% CI 1.9-3.3] among new cases and 14% [95% CI 7.7-21] among previously treated cases). The rapid sputum collection and transportation mechanism implemented in the survey demonstrates its feasibility in low resource settings and should be replicated for routinely transporting TB specimens from microscopy labs to GeneXpert sites. Establishment of in-country capacity for rapid molecular diagnostics for both first- and second-line DST is an immediate need for achieving universal drug susceptibility testing (DST) to guide appropriate patient management.

Keywords: Anti-TB Drug Resistance Survey; Rifampicin resistance; Timor-Leste; Whole genome sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Timor-Leste’s anti-TB drug resistance survey sample processing workflow. SS +  = sputum smear-positive (on microscopy); Prev Treated = previously treated; RIF = rifampicin; RR-TB = rifampicin-resistant TB (including MDR-TB); RS-TB = rifampicin-susceptible TB; pDST = phenotypic DST; WGS = whole genome sequencing; NTRL = National TB Reference Laboratory; SNRL = Supranational Laboratory
Fig. 2
Fig. 2
Age/sex population structure of bacteriologically confirmed pulmonary TB patients
See this image and copyright information in PMC

References

    1. WHO. Timor-Leste. Country Profiles. Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Available at http://www.who.int/tb/country/data/profiles/en/. Last accessed on 08 Feb 2022.
    1. WHO SEARO. Annual Report 2017. Bending the curve – Ending TB. Available at: http://apps.who.int/iris/bitstream/10665/254762/1/978929022584-eng.pdf. Last accessed on 08 Feb 2022.
    1. WHO Global TB Report 2019, Timor-Leste Country Profile. Available at: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&i.... Last accessed on 08 Feb 2022.
    1. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Geneva: World Health Organization. 2020. Licence: CC BY-NC-SA 3.0 IGO.
    1. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Available at https://www.who.int/publications/i/item/9789240007048. Last accessed on 08 Feb 2022. - PubMed

Publication types

MeSH terms

LinkOut - more resources